ClinicalTrials.gg
TerminatedNCT06897579Updated Apr 28, 2026

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

A Phase 2 interventional study of Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule and Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection in Extensive Stage Small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 32 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.

Enrollment
20th of 36
40 · median 48
Started
2025
with 1 other
Phase 2
22 of 36
4 open now
Registered
36th of 36
by date

Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 20th largest by enrollment, is one of 2 that started in 2025, is one of 22 in phase 2, and was the 36th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing carboplatin in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus carboplatin/cisplatin + etoposide + Tislelizumab sequential Tislelizumab in the first-line treatment of extensive stage small cell lung cancer.

03

Conditions studied

  • Extensive Stage Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined the study, signed the , and had good compliance;
  • 18 years old ≤age≤ 75 years old (calculated on the date of signing the informed consent);
  • (ECOG) score 0 \~ 1;
  • Expected survival greater than 12 weeks.
  • or cytologically confirmed Extensive stage small cell lung cancer (ES-SCLC) (according to the Veterans Administration Lung Cancer Society (VALG) disease staging system).
  • had not received systemic therapy for ES-SCLC (including systemic chemotherapy, molecular targeted drug therapy, biological therapy and other therapeutic drugs, etc.) or therapy.
  • Patients receiving chemoradiotherapy for previously limited-stage SCLC must be treated for cure, and there must be a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive SCLC.
  • Confirmed presence of at least one according to 1.1 criteria. Note: Measurable target lesions cannot be selected from previous radiotherapy sites. If the target lesion of the previous radiotherapy site is the only alternative target lesion, the investigator should provide pre - and post-imaging data showing significant progression of the lesion.
  • Laboratory inspection meets the following standards:

    1. (HGB) ≥ 90g/L;
    2. Neutrophil absolute value (NEUT) ≥ 1.5× 10 9 /L;
    3. count (PLT) ≥ 90× 10 9 /L;
    4. Total (TBIL) ≤ 1.5 times the value (ULN);
    5. Alanine transferase () and aspartate transferase (AST) ≤ 2.5×ULN. ALT and AST≤ 5×ULN if accompanied by liver ;
    6. Serum creatinine (CR) ≤ 1.5×ULN or (CCR) ≥60 mL /min;
    7. (PT), activated partial thromboplastin time (APTT), International standardized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy).
  • Women of reproductive age should agree that effective must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Had or was currently suffering from other malignant tumors within 3 years prior to the first medication. The following two conditions can be included: other treated with a single operation, achieving continuous 5-year disease-free survival (DFS); Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta(non-invasive tumor), Tis (cancer in situ) and T1 (tumor infiltrating basal membrane)].
  • The presence of diseases affecting intravenous administration, intravenous blood collection, or multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction);
  • The adverse effects of previous treatment did not return to The (CTCAE) v5.0 score ≤ 1, except for grade 2 alopecia, grade 2 peripheral neurotoxicity, grade 2 anemia, non- and asymptomatic laboratory abnormalities, stable hypothyroidism after hormone replacement therapy and other toxicities deemed by the investigators to be of no safety risk.
  • Those who have received major surgical treatment, significant traumatic injury, or major surgery during the intended study treatment period (other than protocol-specified surgery) within the 4 weeks prior to initial medication, or have sustained unhealed wounds or fractures. (Major surgery is defined as surgery at grade 3 and above in the National Surgical Grading Directory 2022 edition).
  • Subjects with any bleeding or bleeding event ≥ CTC AE grade 3 within 4 weeks prior to initial dosing.
  • Patients who experienced a hyperarterial/venous thrombosis event, such as cerebrovascular accident (including ), deep vein thrombosis and pulmonary embolism, within 6 months before the first administration of the drug.
  • Active viral hepatitis and poorly controlled. Those who meet the following requirements can be screened: positive subjects must meet Hepatitis B virus (HBV) DNA quantification \<2000 IU/ml (or 1*104 copy/ml) or receive anti-HBV therapy with a 10-fold (1 log) or greater reduction in viral index for at least 1 week prior to study initiation, and subjects are willing to receive anti-HBV therapy throughout the study period; infected persons (HCV Ab or HCV RNA positive) : The investigators judged to be in a stable state or were receiving antiviral therapy at enrollment and continued to receive approved antiviral therapy in the study.
  • Patients with active syphilis who need treatment;
  • There is a history of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment, or active pneumonia with clinical symptoms.
  • Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders.
  • People who are preparing for or have previously received bone marrow transplantation or solid organ transplantation.
  • History of hepatic encephalopathy.
  • Major cardiovascular disease, including any of the following:

    1. According to the (NYHA) standards of grade II or higher cardiac insufficiency or heart color ultrasound: (LVEF) \<50%;
    2. There is a history of clinically significant ventricular arrhythmias (such as persistent ventricular tachycardia, ventricular fibrillation, tip torsion ventricular tachycardia) or arrhythmias requiring continuous antiarrhythmic drug treatment;
    3. Unstable angina;
    4. Myocardial infarction occurred within 12 months;
    5. Fridericia- modified (QTcF) > 450 ms (msec) for men and >470 msec for women (if QTc is abnormal, it can be tested three times at intervals of more than 2 minutes, and its average value is taken);
    6. Congenital long QT syndrome history or family history;
    7. A history of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolism within the 3 months prior to randomization (implantable venous port or catheter-derived thrombosis, or superficial venous thrombosis is not considered "severe" thromboembolism);
    8. Currently receiving or having recently received (within 7 days before the start of study treatment) aspirin (>325mg/ day (maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol.
  • Active or uncontrolled severe infection (≥CTC AE grade 2 infection);
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • Have a history of immunodeficiency, including positive or other acquired or congenital immunodeficiency diseases;
  • Subjects who require , systemic, or absorbable topical hormone therapy for immunosuppressive purposes and who continue to use it for 7 days prior to initial administration (except for \< 10 mg daily prednisone or other therapeutic hormones);
  • People who have epilepsy and need treatment.
  • Tumor-related symptoms and treatment:

    1. For subjects who have received chemotherapy, immunotherapy within 3 weeks before the first dose, radiation therapy or small molecule targeted drugs within 2 weeks, or who are still within the 5 half-lives of the drug (as the shortest time of occurrence), the is calculated from the end time of the last treatment;
    2. Within 2 weeks before the first drug use, it has been treated with Chinese patent medicines (including compound Cantharides capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Bruceae oil injection/capsule, Xiaoaiping tablet/injection, Cinobufotalin capsule, etc.) with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions;
    3. Imaging (CT or MRI) shows that the tumor has invaded important blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels during the follow-up study period and cause fatal massive bleeding;
    4. Uncontrolled pleural effusion, pericardial effusion or moderate to severe ascites that still require repeated drainage (investigators' judgment);
    5. Patients with active central nervous system (CNS) and/or cancerous meningitis identified by known or screening tests. Subjects with asymptomatic (i.e., no progressive central nervous system symptoms caused by brain metastases, no need for corticosteroids, and the lesion size ≤1.5cm) can participate, but require regular brain imaging as a disease site. (2) Treated subjects with BMS who had stable BMS for at least 2 months (as determined by two imaging studies at least 4 weeks apart after BMS), no evidence of new or expanded BMS, and steroid discontinuation 3 days before study drug administration. Stable brain metastases in this definition should be determined before the first administration of the drug.
    6. Spinal cord compression that was not treated radically by surgery and/or radiotherapy, or previously diagnosed spinal cord compression with no clinical evidence of disease stabilization ≥1 week after treatment prior to randomization.
  • Known allergy to study drug , known severe allergic reaction to any monoclonal antibody, history of carboplatin, cisplatin, or etoposide allergy.
  • Subjects had previously been treated with other antibodies/drugs targeting immune checkpoints, such as , PD-L1, CTLA4, etc.
  • Previously received treatment with anti-angiogenic drugs such as Anlotinib, Apatinib, and Bevacizumab.
  • Participants who had participated in and used other anti-tumor clinical trials within 4 weeks before the first medication.
  • In the judgment of the investigator, there is a situation that seriously endangers the safety of the subject or affects the completion of the study.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Carboplatin/cisplatin + etoposide + benmelstobart + Anlotinib hydrochloride

    Induction treatment period:Carboplatin for injection/Cisplatin for injection + etoposide injection + benmelstobart injection, intravenous infusion, 21 days 1 cycle (etoposide injection on the 2nd and 3rd day of each cycle) Maintenance treatment period: benmelstobart injection, intravenous drip, 21 days 1 cycle;Anlotinib hydrochloride capsules were taken orally on an empty stomach for 2 consecutive weeks and stopped for 1 week.

    Drug: Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule

  • Active comparator
    Carboplatin /Cisplatin + etoposide + Tislelizumab

    Induction treatment period:Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection, intravenous infusion, 21 days, 1 cycle (etoposide injection on the 2nd and 3rd day of each cycle) Maintenance treatment period:Tislelizumab injection, intravenous drip, 21 days 1 cycle.

    Drug: Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection

Interventions

  • DrugCarboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule

    Drug pages: Carboplatin · Cisplatin · Etoposide · Benmelstobart · Catequentinib hydrochloride

    Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction/Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Bemosubebezumab injection is a humanized recombinant anti-Programmed cell death ligand 1 (PD-L1) monoclonal antibody/Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.

  • DrugCarboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection

    Drug pages: Carboplatin · Cisplatin · Etoposide · Tislelizumab

    Carboplatin for injection inhibits DNA synthesis and thus prevents the division and reproduction of cancer cells/Cisplatin for injection binds to DNA and interferes with the DNA replication and transcription process, thereby inhibiting the proliferation of tumor cells/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    The time from enrollment until the first onset of disease progression or death from any cause, whichever occurs first.

    Time frame: From enrollment until the first onset of disease progression or death from any cause, evaluation is expected to take 2 years

Secondary outcomes

  1. 12/24 month PFS rate

    The percentage of subjects with no progression from the first dose to 12 and 24 months of total subjects.

    Time frame: 12-month, 24-month

  2. 12/24 month Overall survival (OS) rate

    The number of surviving subjects as a percentage of the total number of subjects from the first dose to 12 and 24 months.

    Time frame: 12-month, 24-month

  3. Overall survival (OS)

    The time between randomization and death from all causes.

    Time frame: From randomization to death from all causes, evaluation is expected to take 5 years

  4. Objective response rate (ORR)

    The proportion of subjects achieving complete response (CR) or partial response (PR) was assessed.

    Time frame: Complete response time was achieved, evaluation is expected to take 2 years

  5. Disease Control Rate (DCR)

    The proportion of subjects who achieved complete response (CR), partial response (PR), or stable disease (SD) was assessed.

    Time frame: Complete response time was achieved, evaluation is expected to take 2 years

  6. Incidence of adverse events (AE) and serious adverse events (SAE)

    The incidence and severity of adverse events were determined according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 rating scale.

    Time frame: Time of adverse event, evaluation is expected to take 2 years

  7. Patient-reported Outcomes (PRO): Treatment of Cancer Quality of Life Questionnaire - Core 30

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30). Treatment of Cancer Quality of Life Questionnaire - Core 30 were used to evaluate PRO. The EORTC QLQ-C30 v3 questionnaire is an established measure of health-related quality of life (HRQoL)Methods, it is often used as the end point of tumor clinical trials.A score of 0-100, where higher scores indicate greater function, higher HRQoL, or higher symptom levels.

    Time frame: PRO assessments were performed during the screening period, at the end of each even-numbered cycle, at the end of study treatment, and at safety follow-up in the order shown, baseline to 2 years

  8. Patient-reported Outcomes (PRO): EORTC QLQ-LC13

    EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) QLQ-LC13 were used to evaluate PRO.The QLQ-LC13 is a 13-item self-filling questionnaire for lung cancer disease that will be associated with the EORTC Use QLQ-C30 together.4-point scale: "Not at all", "somewhat", "quite a bit" and "to a great extent"

    Time frame: PRO assessments were performed during the screening period, at the end of each even-numbered cycle, at the end of study treatment, and at safety follow-up in the order shown, baseline to 2 years

  9. Patient-reported Outcomes (PRO): European Quality of Life-5 Dimensions 5 Levels

    European Quality of Life-5 Dimensions 5 Levels were used to evaluate PRO. EuroQol- 5 Dimension (EQ-5D) is a standardized health status indicator developed by the EuroQol group, which asseses five dimensions: mobility, self-care, general activity, pain/discomfort, and anxiety/depression.Each dimension has five response options that reflect increased difficulty (no problem, some problem, moderate problem, severe)Serious problem (extremely serious problem).

    Time frame: PRO assessments were performed during the screening period, at the end of each even-numbered cycle, at the end of study treatment, and at safety follow-up in the order shown, baseline to 2 years

07

Study locations

32 sites
  • Maanshan People's Hospital
    Maanshan, Anhui 243000, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100000, China
  • Peking University People´s Hospital
    Beijing, Beijing Municipality 100044, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Fujian Medical University 2nd Affiliated Hospital
    Quanzhou, Fujian 362001, China
  • The Second Hospitai. & Clinicae Medical School . Lanzhou University
    Lanzhou, Gansu 730030, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 510000, China
  • Nanfang Hospital
    Guangzhou, Guangzhou 510515, China
  • The fourth hospital of hebei medical university
    Shijiazhuang, Hebei 05000, China
  • Tangshan People's Hospital
    Tangshan, Hebei 063001, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150000, China
  • The Second People's Hosital of Jiaozuo
    Jiaozuo, Henan 454001, China
  • Henan Provincial People'S Hospital
    Zhengzhou, Henan 450003, China
  • Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
    Zhengzhou, Henan 457000, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434000, China
  • Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Baotou Cancer Hospital
    Baotou, Inner Mongolia 014000, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
  • The First Affiliated Hospital of Jinzhou Medical University
    Jinzhou, Liaoning 121001, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110000, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110000, China
  • Shenyang Tenth People's Hospital
    Shenyang, Liaoning 110044, China
  • The First Affiliated Hospital of Shandong First Medical University
    Jinnan, Shandong 250000, China
  • Linyi City People's Hospital
    Linyi, Shandong 276003, China
  • The Second Affiliated Hospital Of Xi'an Jiaotong University
    Xi'an, Shannxi 710000, China
  • Shanxi Cancer hospital
    Taiyuan, Shanxi 30000, China
  • Sichuan cancer hospital
    Chengdu, Sichuan 610042, China
  • Dongyang Municipal People's Hospital
    Dongyang, Zhejiang 522031, China
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, Zhejiang 315000, China
  • Ningbo No.2 Hospital
    Ningbo, Zhejiang 315010, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 317000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Apr 2026, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 27, 2025
StartActual
Apr 7, 2025
Primary completionActual
Apr 15, 2026
CompletionActual
Apr 15, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06897579
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Apr 7, 2025
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026
Last update
Apr 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Cisplatin · Etoposide · Benmelstobart · Catequentinib hydrochloride

Start the discussion